Syndicate
| ShowHide Related Items >><< ALNA Allena Pharmaceuticals - 11/09/20
- Allena Pharmaceuticals CFO Edward Wholihan to step down
- 11/09/20
- Allena expects cash, cash equivalents to fund requirement into 4Q21
- 10/05/20
- Allena Pharmaceuticals appoints Ann Miller to board of directors
- 09/30/20
- Allena enters $25M convertible debt financing, extends cash runway into 4Q21
ALNA Allena Pharmaceuticals - 10/01/20 B. Riley Securities
- Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
- 06/01/20 H.C. Wainwright
- Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
- 03/18/20 Roth Capital
- Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
- 02/12/20 Roth Capital
- Streamlining makes Allena URIROX-2 path clear, says Roth Capital
ALNA Allena Pharmaceuticals - 11/09/20
- Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c)
- 08/05/20
- Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c)
|
Conference/Events
|
Virtual Healthcare… Virtual Healthcare Conference will be held on November 17-19. ShowHide Related Items >><< - 11/17/20
- Syneos Health appoints Larry Pickett as chief information, digital officer
- 10/28/20
- Syneos Health to acquire Synteract
- 07/13/20
- Syneos Health signs service agreement with Pfizer
- 05/28/20
- Syneos Health, Daiichi Sankyo agree to develop ADC Oncology pipeline
SMMNY Siemens Healthineers - 10/15/20
- Varian stockholders approve combination with Siemens Healthineers
- 09/30/20
- Siemens Healthineers, WakeMed announce pact to advance care, improve outcomes
- 09/21/20
- Siemens Healthineers announces diagnostic test collaboration with Novartis
- 09/02/20
- Siemens Healthineers launches cash capital increase
- 10/26/20
- Seelos Therapeutics issued composition of matter patent for SLS-007
- 09/23/20
- Seelos Therapeutics signs research agreement with Duke University in Parkinson's
- 09/14/20
- Seelos Therapeutics issued patent from Japanese Patent Office covering SLS-002
- 09/10/20
- Seelos Therapeutics granted additional US patent for Trehalose
- 11/16/20
- Spark Therapeutics appoints Michael Retterath as CSO
- 11/13/20
- Halozyme: CHMP recommends EU approval of Roche's Phesgo
- 10/29/20
- Roche receives FDA approval for cobas EGFR Mutation Test v2
- 10/22/20
- Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527
- 10/27/20
- RadNet forms JV with CommonSpirit Health
- 08/10/20
- RadNet is evaluating the re-opening of locations
- 08/06/20
- RadNet, Hologic collaborate on use of A.I. in breast health
- 11/04/20
- Prothena announces presentations on two programs on Alzheimer's Disease
- 10/20/20
- Prothena, Roche to advance prasinezumab into late-stage clinical development
- 09/11/20
- Prothena says prasinezumab slows progression on measures of Parkinson's disease
OPNT Opiant Pharmaceuticals - 10/29/20
- Opiant partners with Aptar Pharma on nasal nalmefen for opiod overdose
- 06/07/20
- Opiant Pharmaceuticals 'disappointed' with court decision in patent case
- 11/18/20
- JPMorgan CEO: 'Thank God we have these vaccines coming'
- 11/17/20
- Moderna announces EMA begins rolling review of mRNA-1273
- 11/16/20
- U.K. government secures 5M doses of Moderna COVID vaccine
- 11/16/20
- Moderna jumps 10% to $97.95 after disclosing 94.5% efficacy in COVID vaccine
- 09/09/20
- Magellan Health, Livongo Health to co-market behavioral health services
- 09/03/20
- Magellan Health appoints David Bourdon as CFO
- 07/22/20
- Magellan Health announces collaboration with Neuromotion
- 07/06/20
- Magellan Health appoints Darren Lehrich as Chief Investor Relations Officer
- 11/10/20
- Inventiva announces conclusions from phase II meeting with FDA
- 11/06/20
- Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed
- 11/02/20
- Inventiva announces publication on role of PPARs in NASH treatment
- 10/19/20
- Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil
- 11/12/20
- iTeos Therapeutics appoints Matthew Roden to board of directors
- 11/11/20
- InMode granted U.S. patent for fractional radiofrequency technology Morpues8
- 09/02/20
- InMode authorizes share repurchase program of up to 1 million shares
- 07/06/20
- InMode announces NMPA approval for 2 InMode platforms in China
- 11/17/20
- ImmunoGen Blastic Plasmacytoid Dendritic Cell Neoplasm treatment gets orphan nod
- 10/19/20
- ImmunoGen and Huadong Medicine announce pact to for mirvetuximab soravtansine
- 10/05/20
- ImmunoGen announces FDA Breakthrough Therapy designation for IMGN632
- 09/17/20
- ImmunoGen announces final data from FOWARD II trial at ESMO
- 10/22/20
- FibroGen presents abstract results on data from roxadustat Phase 3 program
- 10/14/20
- FibroGen to present efficacy, safety analyses from Roxadustat Phase 3 Program
- 09/08/20
- FibroGen appoints Percy Carter as CSO
- 09/03/20
- FibroGen jumps after Akebia trial misses safety endpoint
- 11/13/20
- Esperion announces results of pooled data from Phase 3 trials of NEXLETOL
- 10/07/20
- Esperion announces results from Phase 3 trials of NEXLETOL Tablets
- 06/22/20
- Esperion, Daiichi Sankyo Europe amend license agreement
- 06/14/20
- Esperion announces pooled analysis from four Phase 3 studies of NEXLETOL
- $234.11 /
-2.205 (-0.93%) - 11/12/20
- Charles River and PathoQuest to expand pact with NGS-based testing laboratory
- 11/03/20
- Charles River CEO sells 22K shares of common stock
CNCE Concert Pharmaceuticals - 09/29/20
- Concert Pharmaceuticals completes patient enrollment in CTP-692 trial
- 07/08/20
- Concert Pharmaceuticals gets FDA Breakthrough Therapy Designation for CTP-543
- 06/12/20
- Concert Pharmaceuticals' CTP-543 ph.2 trial data saw 'positive findings'
- 11/17/20
- Caladrius CMO Dr. Douglas Losordo resigns, Robert Honigberg, M.D named interim
- 11/02/20
- Caladrius appoints Anne Whitaker to board of directors
- 10/08/20
- Caladrius opens PoC study of CLBS119 in COVID-19-induced lung damage
- 09/09/20
- Caladrius announces registration of HONEDRA trademark, patent in Japan
- 10/27/20
- SWK Holdings unit receives $2.5M milestone payment from Cara Therapeutics
- 10/20/20
- Vifor Pharma, Cara Therapeutics enter license agreement for Korsuva Injection
- 10/01/20
- Cara Therapeutics appoints Thomas Reilly as CFO
- 06/30/20
- Cara Therapeutics appoints Susan Shiff to board of directors
- 07/22/20
- AxoGen RECON study completes target enrollment of 220 subjects
- 07/01/20
- AxoGen announces seven-year financing agreement with Oberland Capital
- 06/01/20
- Axogen general counsel Greg Freitag retires
ALNA Allena Pharmaceuticals - 11/09/20
- Allena Pharmaceuticals CFO Edward Wholihan to step down
- 11/09/20
- Allena expects cash, cash equivalents to fund requirement into 4Q21
- 10/05/20
- Allena Pharmaceuticals appoints Ann Miller to board of directors
- 09/30/20
- Allena enters $25M convertible debt financing, extends cash runway into 4Q21
- 11/17/20 Benchmark
- Inovio on 'top-10 vaccine contenders list,' says Benchmark
- 11/17/20 Maxim
- Co-Diagnostics price target lowered to $20 from $30 at Maxim
- 11/17/20 Roth Capital
- Inovio downgraded to Sell at Roth Capital on increased competition
- 11/17/20 Redburn
- Moderna initiated with a Sell at Redburn
- 10/26/20 H.C. Wainwright
- ImmunoGen assumed with a Buy at H.C. Wainwright
- 10/19/20 Piper Sandler
- Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
- 10/05/20 Piper Sandler
- Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
- 10/02/20 Guggenheim
- ImmunoGen upgraded to Buy from Neutral at Guggenheim
- 11/10/20 Credit Suisse
- Esperion upgraded to Outperform from Neutral at Credit Suisse
- 09/29/20 JPMorgan
- Esperion resumed with an Underweight at JPMorgan
- 08/10/20 Credit Suisse
- Esperion downgraded to Neutral from Outperform at Credit Suisse
- 05/07/20 Citi
- Esperion price target raised to $56 from $46 at Citi
- $234.11 /
-2.205 (-0.93%) - 11/03/20 Truist
- Charles River price target raised to $256 from $237 at Truist
- 10/30/20 Deutsche Bank
- Charles River price target raised to $250 from $235 at Deutsche Bank
- 09/14/20 Argus
- Charles River price target raised to $235 from $190 at Argus
- 09/10/20
- Fly Intel: Top five analyst upgrades
- 10/22/20 Guggenheim
- AxoGen initiated with a Buy at Guggenheim
- 06/16/20 Cantor Fitzgerald
- AxoGen assumed with an Overweight at Cantor Fitzgerald
- 06/15/20 Cantor Fitzgerald
- AxoGen assumed with an Overweight at Cantor Fitzgerald
- 05/07/20 Canaccord
- AxoGen downgraded to Hold at Canaccord
- 10/21/20 Canaccord
- InMode price target raised to $51 from $42 at Canaccord
- 10/13/20 Baird
- InMode price target raised to $55 from $43 at Baird
- 02/19/20 Barclays
- InMode price target raised to $48 from $45 at Barclays
- 01/28/20 Baird
- InMode price target raised to $55 from $45 at Baird
- 10/21/20 Cantor Fitzgerald
- Prothena price target raised to $24 from $20 at Cantor Fitzgerald
- 07/09/20 Oppenheimer
- Prothena upgraded to Outperform at Oppenheimer
- 07/09/20 Oppenheimer
- Prothena upgraded to Outperform from Perform at Oppenheimer
- 11/19/19 Evercore ISI
- Prothena upgraded to Outperform on valuation at Evercore ISI
- 10/06/20 Mizuho
- Syneos Health upgraded to Buy on attractive entry point at Mizuho
- 10/06/20 Mizuho
- Syneos Health upgraded to Buy from Neutral at Mizuho
- 10/01/20 Goldman Sachs
- Syneos Health upgraded to Buy from Neutral at Goldman Sachs
- 08/12/20 Truist
- Syneos Health price target raised to $80 from $74 at Truist
- 09/03/20 Clarus
- Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals - 10/26/20 Raymond James
- FibroGen initiated with an Underperform at Raymond James
- 10/26/20 Raymond James
- FibroGen initiated with an Underperform at Raymond James
- 10/23/20 Stifel
- FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
- 09/04/20 Stifel
- FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
- 11/13/20
- Fly Intel: Top five analyst upgrades
- 11/13/20 Stephens
- Magellan Health upgraded to Overweight from Equal Weight at Stephens
- 11/11/20 Truist
- Opthea initiated with a Buy at Truist
- 10/16/20 UBS
- Roche price target lowered to CHF 370 from CHF 390 at UBS
- 10/06/20 Goldman Sachs
- Goldman reiterates $34 target on Kiniksa after 'impressive' data
- 09/29/20 Berenberg
- Roche initiated with a Hold at Berenberg
- 10/20/20 H.C. Wainwright
- Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
- 04/22/20 Cantor Fitzgerald
- Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
- 04/21/20 H.C. Wainwright
- Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
- 01/10/20 Stifel
- Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
- 10/13/20 Roth Capital
- Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
- 08/17/20 H.C. Wainwright
- Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
- 08/05/20
- Fly Intel: Top five analyst initiations
- 08/05/20 Roth Capital
- Inventiva initiated with a Buy at Roth Capital
- 10/07/20 Baird
- iTeos Therapeutics initiated with an Outperform at Baird
- 09/18/20 Piper Sandler
- Piper Sandler lays out next potential takeover targets in oncology
- 09/01/20 Piper Sandler
- iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
- 08/18/20 SVB Leerink
- SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
- 05/22/20 Brookline
- Caladrius initiated with a Buy at Brookline
- 05/18/20 Dawson James
- Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals - 10/01/20 B. Riley Securities
- Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
- 06/01/20 H.C. Wainwright
- Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
- 03/18/20 Roth Capital
- Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
- 02/12/20 Roth Capital
- Streamlining makes Allena URIROX-2 path clear, says Roth Capital
- 09/09/20 Roth Capital
- Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
- 06/23/20 Roth Capital
- Seelos Therapeutics price target raised to $12 from $8 Roth Capital
SMMNY Siemens Healthineers - 11/10/20 Credit Suisse
- Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
- 10/28/20 Barrington
- Varian Medical downgraded to Underperform from Outperform at Barrington
- 10/26/20 RBC Capital
- Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
- 10/06/20 Deutsche Bank
- Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals - 11/04/20 JMP Securities
- Concert Pharmaceuticals resumed with an Outperform at JMP Securities
- 03/30/20
- Fly Intel: Top five analyst initiations
- 03/30/20 Jefferies
- Concert Pharmaceuticals initiated with a Buy at Jefferies
- 02/27/20 Stifel
- Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
- 10/29/20
- Syneos Health raises FY20 adjusted EPS view to $3.33-$3.46 from $3.16-$3.38
- 10/29/20
- Syneos Health reports Q3 adjusted EPS $1.04, consensus 91c
- 08/06/20
- Syneos Health sees FY20 adjusted EPS $3.16-$3.38, consensus $2.98
- 08/06/20
- Syneos Health reports Q2 adjusted EPS 58c, consensus 48c
- 10/27/20
- Oncolytics announces new GI cancer study using
- 10/15/20
- Roche confirms outlook for 2020 based on assessment of COVID-19
- 10/15/20
- Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year
- 09/11/20
- Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS
- 11/09/20
- RadNet reports Q3 adjusted EPS 15c, consensus (8c)
- 10/20/20
- RadNet executes partnership agreement with Adventist Health
- 08/10/20
- RadNet reports Q2 adjusted EPS (16c), consensus (44c)
- 11/04/20
- Prothena reports Q3 EPS (77c), consensus (65c)
- 08/06/20
- Prothena reports Q2 EPS (66c), consensus (61c)
OPNT Opiant Pharmaceuticals - 11/12/20
- Opiant Pharmaceuticals reports Q3 EPS 15c, consensus (21c)
- 08/06/20
- Opiant Pharmaceuticals reports Q2 EPS (45c), consensus (24c)
- 10/29/20
- Moderna reports Q3 EPS (59c), consensus (43c)
- 10/28/20
- Notable companies reporting before tomorrow's open
- 08/05/20
- Moderna reports Q2 EPS (31c), consensus (35c)
- 10/29/20
- Magellan Health backs 2020 adjusted EPS view 63c-$1.10, consensus 91c
- 10/29/20
- Magellan Health reports Q3 EPS 8c, consensus (10c)
- 07/29/20
- Magellan Health sees FY20 adjusted EPS 63c-$1.10, consensus $2.88
- 07/29/20
- Magellan Health reports Q2 adjusted EPS 84c, consensus 82c
- 11/12/20
- iTeos Therapeutics reports Q3 EPS (48c), consensus (36c)
- 09/01/20
- iTeos Therapeutics reports Q2 EPS ($29.49) vs. ($36.49) a year ago
- 11/12/20
- InMode reports Q3 non-GAAP EPS 63c, consensus 48c
- 10/13/20
- InMode sees FY20 revenue $192M-$195M, consensus $159.91M
- 10/13/20
- InMode sees Q3 non-GAAP EPS 60c-62c, consensus 31c
- 08/05/20
- InMode sees FY20 revenue $156M-$160M, consensus $143.04M
- 11/06/20
- ImmunoGen still sees 2020 revenue $60M-$65M, consensus $66.96M
- 11/06/20
- ImmunoGen reports Q3 EPS (13c), consensus (18c)
- 07/31/20
- ImmunoGen backs 2020 revenue view $60M-$65M, consensus $63.12M
- 07/31/20
- ImmunoGen reports Q2 EPS (14c), consensus (17c)
- 11/05/20
- FibroGen reports Q3 EPS 35c, consensus (80c)
- 08/06/20
- FibroGen sees ending year with $720M-$730M in cash, cash equivalents
- 08/06/20
- FibroGen reports Q2 EPS (95c), consensus (64c)
- 08/10/20
- Esperion sees further cash to be provided from U.S. product sales
- 08/10/20
- Esperion reports Q2 EPS $4.32, consensus $1.71
- $234.11 /
-2.205 (-0.93%) - 10/29/20
- Charles River sees low-to mid-single-digit percentage growth in Q4 non-GAAP EPS
- 10/29/20
- Charles River raises FY20 EPS view to $7.75-$7.85 from $7.05-$7.35
- 10/29/20
- Charles River reports Q3 EPS $2.33, consensus $1.80
- 08/05/20
- Charles River raises FY20 adj. EPS view to $7.05-$7.35 from $6.75-$7.10
CNCE Concert Pharmaceuticals - 11/05/20
- Concert Pharmaceuticals reports Q3 EPS (60c), consensus (75c)
- 08/06/20
- Concert Pharmaceuticals reports Q2 EPS (41c), consensus (69c)
- 11/05/20
- Caladrius reports Q3 EPS (29c), consensus (29c)
- 08/13/20
- Caladrius reports Q2 EPS (50c), consensus (39c)
- 11/09/20
- Cara Therapeutics reports Q3 EPS (35c), consensus (60c)
- 08/10/20
- Cara Therapeutics reports Q2 EPS (54c), consensus (67c)
- 10/29/20
- AxoGen reports Q3 EPS 4c, consensus (14c)
- 08/05/20
- AxoGen reports Q2 EPS (20c), consensus (38c)
- 07/01/20
- AxoGen sees Q3, Q4 revenue below prior-year levels
- 07/01/20
- AxoGen sees Q2 revenue at least $21M, cosensus $11.67M
ALNA Allena Pharmaceuticals - 11/09/20
- Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c)
- 08/05/20
- Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c)
|
Conference/Events
|
Virtual Healthcare… Virtual Healthcare Conference will be held on November 17-19. ShowHide Related Items >><< - 11/17/20
- Syneos Health appoints Larry Pickett as chief information, digital officer
- 10/28/20
- Syneos Health to acquire Synteract
- 07/13/20
- Syneos Health signs service agreement with Pfizer
- 05/28/20
- Syneos Health, Daiichi Sankyo agree to develop ADC Oncology pipeline
SMMNY Siemens Healthineers - 10/15/20
- Varian stockholders approve combination with Siemens Healthineers
- 09/30/20
- Siemens Healthineers, WakeMed announce pact to advance care, improve outcomes
- 09/21/20
- Siemens Healthineers announces diagnostic test collaboration with Novartis
- 09/02/20
- Siemens Healthineers launches cash capital increase
- 10/26/20
- Seelos Therapeutics issued composition of matter patent for SLS-007
- 09/23/20
- Seelos Therapeutics signs research agreement with Duke University in Parkinson's
- 09/14/20
- Seelos Therapeutics issued patent from Japanese Patent Office covering SLS-002
- 09/10/20
- Seelos Therapeutics granted additional US patent for Trehalose
- 11/16/20
- Spark Therapeutics appoints Michael Retterath as CSO
- 11/13/20
- Halozyme: CHMP recommends EU approval of Roche's Phesgo
- 10/29/20
- Roche receives FDA approval for cobas EGFR Mutation Test v2
- 10/22/20
- Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527
- 10/27/20
- RadNet forms JV with CommonSpirit Health
- 08/10/20
- RadNet is evaluating the re-opening of locations
- 08/06/20
- RadNet, Hologic collaborate on use of A.I. in breast health
- 11/04/20
- Prothena announces presentations on two programs on Alzheimer's Disease
- 10/20/20
- Prothena, Roche to advance prasinezumab into late-stage clinical development
- 09/11/20
- Prothena says prasinezumab slows progression on measures of Parkinson's disease
OPNT Opiant Pharmaceuticals - 10/29/20
- Opiant partners with Aptar Pharma on nasal nalmefen for opiod overdose
- 06/07/20
- Opiant Pharmaceuticals 'disappointed' with court decision in patent case
- 11/17/20
- Moderna announces EMA begins rolling review of mRNA-1273
- 11/16/20
- U.K. government secures 5M doses of Moderna COVID vaccine
- 11/16/20
- Moderna jumps 10% to $97.95 after disclosing 94.5% efficacy in COVID vaccine
- 11/16/20
- Moderna COVID-19 vaccine candidate meets efficacy endpoint in Phase 3 study
- 09/09/20
- Magellan Health, Livongo Health to co-market behavioral health services
- 09/03/20
- Magellan Health appoints David Bourdon as CFO
- 07/22/20
- Magellan Health announces collaboration with Neuromotion
- 07/06/20
- Magellan Health appoints Darren Lehrich as Chief Investor Relations Officer
- 11/10/20
- Inventiva announces conclusions from phase II meeting with FDA
- 11/06/20
- Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed
- 11/02/20
- Inventiva announces publication on role of PPARs in NASH treatment
- 10/19/20
- Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil
- 11/12/20
- iTeos Therapeutics appoints Matthew Roden to board of directors
- 11/11/20
- InMode granted U.S. patent for fractional radiofrequency technology Morpues8
- 09/02/20
- InMode authorizes share repurchase program of up to 1 million shares
- 07/06/20
- InMode announces NMPA approval for 2 InMode platforms in China
- 11/17/20
- ImmunoGen Blastic Plasmacytoid Dendritic Cell Neoplasm treatment gets orphan nod
- 10/19/20
- ImmunoGen and Huadong Medicine announce pact to for mirvetuximab soravtansine
- 10/05/20
- ImmunoGen announces FDA Breakthrough Therapy designation for IMGN632
- 09/17/20
- ImmunoGen announces final data from FOWARD II trial at ESMO
- 10/22/20
- FibroGen presents abstract results on data from roxadustat Phase 3 program
- 10/14/20
- FibroGen to present efficacy, safety analyses from Roxadustat Phase 3 Program
- 09/08/20
- FibroGen appoints Percy Carter as CSO
- 09/03/20
- FibroGen jumps after Akebia trial misses safety endpoint
- 11/13/20
- Esperion announces results of pooled data from Phase 3 trials of NEXLETOL
- 10/07/20
- Esperion announces results from Phase 3 trials of NEXLETOL Tablets
- 06/22/20
- Esperion, Daiichi Sankyo Europe amend license agreement
- 06/14/20
- Esperion announces pooled analysis from four Phase 3 studies of NEXLETOL
- 11/12/20
- Charles River and PathoQuest to expand pact with NGS-based testing laboratory
- 11/03/20
- Charles River CEO sells 22K shares of common stock
CNCE Concert Pharmaceuticals - 09/29/20
- Concert Pharmaceuticals completes patient enrollment in CTP-692 trial
- 07/08/20
- Concert Pharmaceuticals gets FDA Breakthrough Therapy Designation for CTP-543
- 06/12/20
- Concert Pharmaceuticals' CTP-543 ph.2 trial data saw 'positive findings'
- 11/17/20
- Caladrius CMO Dr. Douglas Losordo resigns, Robert Honigberg, M.D named interim
- 11/02/20
- Caladrius appoints Anne Whitaker to board of directors
- 10/08/20
- Caladrius opens PoC study of CLBS119 in COVID-19-induced lung damage
- 09/09/20
- Caladrius announces registration of HONEDRA trademark, patent in Japan
- 10/27/20
- SWK Holdings unit receives $2.5M milestone payment from Cara Therapeutics
- 10/20/20
- Vifor Pharma, Cara Therapeutics enter license agreement for Korsuva Injection
- 10/01/20
- Cara Therapeutics appoints Thomas Reilly as CFO
- 06/30/20
- Cara Therapeutics appoints Susan Shiff to board of directors
- 07/22/20
- AxoGen RECON study completes target enrollment of 220 subjects
- 07/01/20
- AxoGen announces seven-year financing agreement with Oberland Capital
- 06/01/20
- Axogen general counsel Greg Freitag retires
ALNA Allena Pharmaceuticals - 11/09/20
- Allena Pharmaceuticals CFO Edward Wholihan to step down
- 11/09/20
- Allena expects cash, cash equivalents to fund requirement into 4Q21
- 10/05/20
- Allena Pharmaceuticals appoints Ann Miller to board of directors
- 09/30/20
- Allena enters $25M convertible debt financing, extends cash runway into 4Q21
- 11/17/20 Benchmark
- Inovio on 'top-10 vaccine contenders list,' says Benchmark
- 11/17/20 Maxim
- Co-Diagnostics price target lowered to $20 from $30 at Maxim
- 11/17/20 Roth Capital
- Inovio downgraded to Sell at Roth Capital on increased competition
- 11/17/20 Redburn
- Moderna initiated with a Sell at Redburn
- 10/26/20 H.C. Wainwright
- ImmunoGen assumed with a Buy at H.C. Wainwright
- 10/19/20 Piper Sandler
- Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
- 10/05/20 Piper Sandler
- Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
- 10/02/20 Guggenheim
- ImmunoGen upgraded to Buy from Neutral at Guggenheim
- 11/10/20 Credit Suisse
- Esperion upgraded to Outperform from Neutral at Credit Suisse
- 09/29/20 JPMorgan
- Esperion resumed with an Underweight at JPMorgan
- 08/10/20 Credit Suisse
- Esperion downgraded to Neutral from Outperform at Credit Suisse
- 05/07/20 Citi
- Esperion price target raised to $56 from $46 at Citi
- 11/03/20 Truist
- Charles River price target raised to $256 from $237 at Truist
- 10/30/20 Deutsche Bank
- Charles River price target raised to $250 from $235 at Deutsche Bank
- 09/14/20 Argus
- Charles River price target raised to $235 from $190 at Argus
- 09/10/20
- Fly Intel: Top five analyst upgrades
- 10/22/20 Guggenheim
- AxoGen initiated with a Buy at Guggenheim
- 06/16/20 Cantor Fitzgerald
- AxoGen assumed with an Overweight at Cantor Fitzgerald
- 06/15/20 Cantor Fitzgerald
- AxoGen assumed with an Overweight at Cantor Fitzgerald
- 05/07/20 Canaccord
- AxoGen downgraded to Hold at Canaccord
- 10/21/20 Canaccord
- InMode price target raised to $51 from $42 at Canaccord
- 10/13/20 Baird
- InMode price target raised to $55 from $43 at Baird
- 02/19/20 Barclays
- InMode price target raised to $48 from $45 at Barclays
- 01/28/20 Baird
- InMode price target raised to $55 from $45 at Baird
- 10/21/20 Cantor Fitzgerald
- Prothena price target raised to $24 from $20 at Cantor Fitzgerald
- 07/09/20 Oppenheimer
- Prothena upgraded to Outperform at Oppenheimer
- 07/09/20 Oppenheimer
- Prothena upgraded to Outperform from Perform at Oppenheimer
- 11/19/19 Evercore ISI
- Prothena upgraded to Outperform on valuation at Evercore ISI
- 10/06/20 Mizuho
- Syneos Health upgraded to Buy on attractive entry point at Mizuho
- 10/06/20 Mizuho
- Syneos Health upgraded to Buy from Neutral at Mizuho
- 10/01/20 Goldman Sachs
- Syneos Health upgraded to Buy from Neutral at Goldman Sachs
- 08/12/20 Truist
- Syneos Health price target raised to $80 from $74 at Truist
- 09/03/20 Clarus
- Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals - 10/26/20 Raymond James
- FibroGen initiated with an Underperform at Raymond James
- 10/26/20 Raymond James
- FibroGen initiated with an Underperform at Raymond James
- 10/23/20 Stifel
- FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
- 09/04/20 Stifel
- FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
- 11/13/20
- Fly Intel: Top five analyst upgrades
- 11/13/20 Stephens
- Magellan Health upgraded to Overweight from Equal Weight at Stephens
- 11/11/20 Truist
- Opthea initiated with a Buy at Truist
- 10/16/20 UBS
- Roche price target lowered to CHF 370 from CHF 390 at UBS
- 10/06/20 Goldman Sachs
- Goldman reiterates $34 target on Kiniksa after 'impressive' data
- 09/29/20 Berenberg
- Roche initiated with a Hold at Berenberg
- 10/20/20 H.C. Wainwright
- Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
- 04/22/20 Cantor Fitzgerald
- Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
- 04/21/20 H.C. Wainwright
- Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
- 01/10/20 Stifel
- Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
- 10/13/20 Roth Capital
- Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
- 08/17/20 H.C. Wainwright
- Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
- 08/05/20
- Fly Intel: Top five analyst initiations
- 08/05/20 Roth Capital
- Inventiva initiated with a Buy at Roth Capital
- 10/07/20 Baird
- iTeos Therapeutics initiated with an Outperform at Baird
- 09/18/20 Piper Sandler
- Piper Sandler lays out next potential takeover targets in oncology
- 09/01/20 Piper Sandler
- iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
- 08/18/20 SVB Leerink
- SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
- 05/22/20 Brookline
- Caladrius initiated with a Buy at Brookline
- 05/18/20 Dawson James
- Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals - 10/01/20 B. Riley Securities
- Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
- 06/01/20 H.C. Wainwright
- Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
- 03/18/20 Roth Capital
- Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
- 02/12/20 Roth Capital
- Streamlining makes Allena URIROX-2 path clear, says Roth Capital
- 09/09/20 Roth Capital
- Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
- 06/23/20 Roth Capital
- Seelos Therapeutics price target raised to $12 from $8 Roth Capital
- 11/18/19 H.C. Wainwright
- Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
SMMNY Siemens Healthineers - 11/10/20 Credit Suisse
- Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
- 10/28/20 Barrington
- Varian Medical downgraded to Underperform from Outperform at Barrington
- 10/26/20 RBC Capital
- Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
- 10/06/20 Deutsche Bank
- Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals - 11/04/20 JMP Securities
- Concert Pharmaceuticals resumed with an Outperform at JMP Securities
- 03/30/20
- Fly Intel: Top five analyst initiations
- 03/30/20 Jefferies
- Concert Pharmaceuticals initiated with a Buy at Jefferies
- 02/27/20 Stifel
- Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
- 10/29/20
- Syneos Health raises FY20 adjusted EPS view to $3.33-$3.46 from $3.16-$3.38
- 10/29/20
- Syneos Health reports Q3 adjusted EPS $1.04, consensus 91c
- 08/06/20
- Syneos Health sees FY20 adjusted EPS $3.16-$3.38, consensus $2.98
- 08/06/20
- Syneos Health reports Q2 adjusted EPS 58c, consensus 48c
- 10/27/20
- Oncolytics announces new GI cancer study using
- 10/15/20
- Roche confirms outlook for 2020 based on assessment of COVID-19
- 10/15/20
- Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year
- 09/11/20
- Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS
- 11/09/20
- RadNet reports Q3 adjusted EPS 15c, consensus (8c)
- 10/20/20
- RadNet executes partnership agreement with Adventist Health
- 08/10/20
- RadNet reports Q2 adjusted EPS (16c), consensus (44c)
- 11/04/20
- Prothena reports Q3 EPS (77c), consensus (65c)
- 08/06/20
- Prothena reports Q2 EPS (66c), consensus (61c)
OPNT Opiant Pharmaceuticals - 11/12/20
- Opiant Pharmaceuticals reports Q3 EPS 15c, consensus (21c)
- 08/06/20
- Opiant Pharmaceuticals reports Q2 EPS (45c), consensus (24c)
- 10/29/20
- Moderna reports Q3 EPS (59c), consensus (43c)
- 10/28/20
- Notable companies reporting before tomorrow's open
- 08/05/20
- Moderna reports Q2 EPS (31c), consensus (35c)
- 10/29/20
- Magellan Health backs 2020 adjusted EPS view 63c-$1.10, consensus 91c
- 10/29/20
- Magellan Health reports Q3 EPS 8c, consensus (10c)
- 07/29/20
- Magellan Health sees FY20 adjusted EPS 63c-$1.10, consensus $2.88
- 07/29/20
- Magellan Health reports Q2 adjusted EPS 84c, consensus 82c
- 11/12/20
- iTeos Therapeutics reports Q3 EPS (48c), consensus (36c)
- 09/01/20
- iTeos Therapeutics reports Q2 EPS ($29.49) vs. ($36.49) a year ago
- 11/12/20
- InMode reports Q3 non-GAAP EPS 63c, consensus 48c
- 10/13/20
- InMode sees FY20 revenue $192M-$195M, consensus $159.91M
- 10/13/20
- InMode sees Q3 non-GAAP EPS 60c-62c, consensus 31c
- 08/05/20
- InMode sees FY20 revenue $156M-$160M, consensus $143.04M
- 11/06/20
- ImmunoGen still sees 2020 revenue $60M-$65M, consensus $66.96M
- 11/06/20
- ImmunoGen reports Q3 EPS (13c), consensus (18c)
- 07/31/20
- ImmunoGen backs 2020 revenue view $60M-$65M, consensus $63.12M
- 07/31/20
- ImmunoGen reports Q2 EPS (14c), consensus (17c)
- 11/05/20
- FibroGen reports Q3 EPS 35c, consensus (80c)
- 08/06/20
- FibroGen sees ending year with $720M-$730M in cash, cash equivalents
- 08/06/20
- FibroGen reports Q2 EPS (95c), consensus (64c)
- 08/10/20
- Esperion sees further cash to be provided from U.S. product sales
- 08/10/20
- Esperion reports Q2 EPS $4.32, consensus $1.71
- 10/29/20
- Charles River sees low-to mid-single-digit percentage growth in Q4 non-GAAP EPS
- 10/29/20
- Charles River raises FY20 EPS view to $7.75-$7.85 from $7.05-$7.35
- 10/29/20
- Charles River reports Q3 EPS $2.33, consensus $1.80
- 08/05/20
- Charles River raises FY20 adj. EPS view to $7.05-$7.35 from $6.75-$7.10
CNCE Concert Pharmaceuticals - 11/05/20
- Concert Pharmaceuticals reports Q3 EPS (60c), consensus (75c)
- 08/06/20
- Concert Pharmaceuticals reports Q2 EPS (41c), consensus (69c)
- 11/05/20
- Caladrius reports Q3 EPS (29c), consensus (29c)
- 08/13/20
- Caladrius reports Q2 EPS (50c), consensus (39c)
- 11/09/20
- Cara Therapeutics reports Q3 EPS (35c), consensus (60c)
- 08/10/20
- Cara Therapeutics reports Q2 EPS (54c), consensus (67c)
- 10/29/20
- AxoGen reports Q3 EPS 4c, consensus (14c)
- 08/05/20
- AxoGen reports Q2 EPS (20c), consensus (38c)
- 07/01/20
- AxoGen sees Q3, Q4 revenue below prior-year levels
- 07/01/20
- AxoGen sees Q2 revenue at least $21M, cosensus $11.67M
ALNA Allena Pharmaceuticals - 11/09/20
- Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c)
- 08/05/20
- Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c)
|
Conference/Events
|
Virtual Healthcare… Virtual Healthcare Conference will be held on November 17-19. ShowHide Related Items >><< - 10/28/20
- Syneos Health to acquire Synteract
- 07/13/20
- Syneos Health signs service agreement with Pfizer
- 05/28/20
- Syneos Health, Daiichi Sankyo agree to develop ADC Oncology pipeline
SMMNY Siemens Healthineers - 10/15/20
- Varian stockholders approve combination with Siemens Healthineers
- 09/30/20
- Siemens Healthineers, WakeMed announce pact to advance care, improve outcomes
- 09/21/20
- Siemens Healthineers announces diagnostic test collaboration with Novartis
- 09/02/20
- Siemens Healthineers launches cash capital increase
- 10/26/20
- Seelos Therapeutics issued composition of matter patent for SLS-007
- 09/23/20
- Seelos Therapeutics signs research agreement with Duke University in Parkinson's
- 09/14/20
- Seelos Therapeutics issued patent from Japanese Patent Office covering SLS-002
- 09/10/20
- Seelos Therapeutics granted additional US patent for Trehalose
- 11/16/20
- Spark Therapeutics appoints Michael Retterath as CSO
- 11/13/20
- Halozyme: CHMP recommends EU approval of Roche's Phesgo
- 10/29/20
- Roche receives FDA approval for cobas EGFR Mutation Test v2
- 10/22/20
- Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527
- 10/27/20
- RadNet forms JV with CommonSpirit Health
- 08/10/20
- RadNet is evaluating the re-opening of locations
- 08/06/20
- RadNet, Hologic collaborate on use of A.I. in breast health
- 11/04/20
- Prothena announces presentations on two programs on Alzheimer's Disease
- 10/20/20
- Prothena, Roche to advance prasinezumab into late-stage clinical development
- 09/11/20
- Prothena says prasinezumab slows progression on measures of Parkinson's disease
OPNT Opiant Pharmaceuticals - 10/29/20
- Opiant partners with Aptar Pharma on nasal nalmefen for opiod overdose
- 06/07/20
- Opiant Pharmaceuticals 'disappointed' with court decision in patent case
- 11/16/20
- U.K. government secures 5M doses of Moderna COVID vaccine
- 11/16/20
- Moderna jumps 10% to $97.95 after disclosing 94.5% efficacy in COVID vaccine
- 11/16/20
- Moderna COVID-19 vaccine candidate meets efficacy endpoint in Phase 3 study
- 11/16/20
- Moderna COVID-19 vaccine candidate reports efficacy of 94.5% in Phase 3 study
- 09/09/20
- Magellan Health, Livongo Health to co-market behavioral health services
- 09/03/20
- Magellan Health appoints David Bourdon as CFO
- 07/22/20
- Magellan Health announces collaboration with Neuromotion
- 07/06/20
- Magellan Health appoints Darren Lehrich as Chief Investor Relations Officer
- 11/10/20
- Inventiva announces conclusions from phase II meeting with FDA
- 11/06/20
- Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed
- 11/02/20
- Inventiva announces publication on role of PPARs in NASH treatment
- 10/19/20
- Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil
- 11/12/20
- iTeos Therapeutics appoints Matthew Roden to board of directors
- 11/11/20
- InMode granted U.S. patent for fractional radiofrequency technology Morpues8
- 09/02/20
- InMode authorizes share repurchase program of up to 1 million shares
- 07/06/20
- InMode announces NMPA approval for 2 InMode platforms in China
- 10/19/20
- ImmunoGen and Huadong Medicine announce pact to for mirvetuximab soravtansine
- 10/05/20
- ImmunoGen announces FDA Breakthrough Therapy designation for IMGN632
- 09/17/20
- ImmunoGen announces final data from FOWARD II trial at ESMO
- 07/20/20
- ImmunoGen appoints Susan Altschuller, PhD as CFO
- 10/22/20
- FibroGen presents abstract results on data from roxadustat Phase 3 program
- 10/14/20
- FibroGen to present efficacy, safety analyses from Roxadustat Phase 3 Program
- 09/08/20
- FibroGen appoints Percy Carter as CSO
- 09/03/20
- FibroGen jumps after Akebia trial misses safety endpoint
- 11/13/20
- Esperion announces results of pooled data from Phase 3 trials of NEXLETOL
- 10/07/20
- Esperion announces results from Phase 3 trials of NEXLETOL Tablets
- 06/22/20
- Esperion, Daiichi Sankyo Europe amend license agreement
- 06/14/20
- Esperion announces pooled analysis from four Phase 3 studies of NEXLETOL
- 11/12/20
- Charles River and PathoQuest to expand pact with NGS-based testing laboratory
- 11/03/20
- Charles River CEO sells 22K shares of common stock
CNCE Concert Pharmaceuticals - 09/29/20
- Concert Pharmaceuticals completes patient enrollment in CTP-692 trial
- 07/08/20
- Concert Pharmaceuticals gets FDA Breakthrough Therapy Designation for CTP-543
- 06/12/20
- Concert Pharmaceuticals' CTP-543 ph.2 trial data saw 'positive findings'
- 11/02/20
- Caladrius appoints Anne Whitaker to board of directors
- 10/08/20
- Caladrius opens PoC study of CLBS119 in COVID-19-induced lung damage
- 09/09/20
- Caladrius announces registration of HONEDRA trademark, patent in Japan
- 08/05/20
- Caladrius CFO Joseph Talamo resigns
- 10/27/20
- SWK Holdings unit receives $2.5M milestone payment from Cara Therapeutics
- 10/20/20
- Vifor Pharma, Cara Therapeutics enter license agreement for Korsuva Injection
- 10/01/20
- Cara Therapeutics appoints Thomas Reilly as CFO
- 06/30/20
- Cara Therapeutics appoints Susan Shiff to board of directors
- 07/22/20
- AxoGen RECON study completes target enrollment of 220 subjects
- 07/01/20
- AxoGen announces seven-year financing agreement with Oberland Capital
- 06/01/20
- Axogen general counsel Greg Freitag retires
ALNA Allena Pharmaceuticals - 11/09/20
- Allena Pharmaceuticals CFO Edward Wholihan to step down
- 11/09/20
- Allena expects cash, cash equivalents to fund requirement into 4Q21
- 10/05/20
- Allena Pharmaceuticals appoints Ann Miller to board of directors
- 09/30/20
- Allena enters $25M convertible debt financing, extends cash runway into 4Q21
- 11/17/20 Maxim
- Co-Diagnostics price target lowered to $20 from $30 at Maxim
- 11/17/20 Roth Capital
- Inovio downgraded to Sell at Roth Capital on increased competition
- 11/17/20 Redburn
- Moderna initiated with a Sell at Redburn
- 11/17/20 BMO Capital
- Moderna downgraded to Market Perform from Outperform at BMO Capital
- 10/26/20 H.C. Wainwright
- ImmunoGen assumed with a Buy at H.C. Wainwright
- 10/19/20 Piper Sandler
- Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
- 10/05/20 Piper Sandler
- Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
- 10/02/20 Guggenheim
- ImmunoGen upgraded to Buy from Neutral at Guggenheim
- 11/10/20 Credit Suisse
- Esperion upgraded to Outperform from Neutral at Credit Suisse
- 09/29/20 JPMorgan
- Esperion resumed with an Underweight at JPMorgan
- 08/10/20 Credit Suisse
- Esperion downgraded to Neutral from Outperform at Credit Suisse
- 05/07/20 Citi
- Esperion price target raised to $56 from $46 at Citi
- 11/03/20 Truist
- Charles River price target raised to $256 from $237 at Truist
- 10/30/20 Deutsche Bank
- Charles River price target raised to $250 from $235 at Deutsche Bank
- 09/14/20 Argus
- Charles River price target raised to $235 from $190 at Argus
- 09/10/20
- Fly Intel: Top five analyst upgrades
- 10/22/20 Guggenheim
- AxoGen initiated with a Buy at Guggenheim
- 06/16/20 Cantor Fitzgerald
- AxoGen assumed with an Overweight at Cantor Fitzgerald
- 06/15/20 Cantor Fitzgerald
- AxoGen assumed with an Overweight at Cantor Fitzgerald
- 05/07/20 Canaccord
- AxoGen downgraded to Hold at Canaccord
- 10/21/20 Canaccord
- InMode price target raised to $51 from $42 at Canaccord
- 10/13/20 Baird
- InMode price target raised to $55 from $43 at Baird
- 02/19/20 Barclays
- InMode price target raised to $48 from $45 at Barclays
- 01/28/20 Baird
- InMode price target raised to $55 from $45 at Baird
- 10/21/20 Cantor Fitzgerald
- Prothena price target raised to $24 from $20 at Cantor Fitzgerald
- 07/09/20 Oppenheimer
- Prothena upgraded to Outperform at Oppenheimer
- 07/09/20 Oppenheimer
- Prothena upgraded to Outperform from Perform at Oppenheimer
- 11/19/19 Evercore ISI
- Prothena upgraded to Outperform on valuation at Evercore ISI
- 10/06/20 Mizuho
- Syneos Health upgraded to Buy on attractive entry point at Mizuho
- 10/06/20 Mizuho
- Syneos Health upgraded to Buy from Neutral at Mizuho
- 10/01/20 Goldman Sachs
- Syneos Health upgraded to Buy from Neutral at Goldman Sachs
- 08/12/20 Truist
- Syneos Health price target raised to $80 from $74 at Truist
- 09/03/20 Clarus
- Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals - 10/26/20 Raymond James
- FibroGen initiated with an Underperform at Raymond James
- 10/26/20 Raymond James
- FibroGen initiated with an Underperform at Raymond James
- 10/23/20 Stifel
- FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
- 09/04/20 Stifel
- FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
- 11/13/20
- Fly Intel: Top five analyst upgrades
- 11/13/20 Stephens
- Magellan Health upgraded to Overweight from Equal Weight at Stephens
- 11/11/20 Truist
- Opthea initiated with a Buy at Truist
- 10/16/20 UBS
- Roche price target lowered to CHF 370 from CHF 390 at UBS
- 10/06/20 Goldman Sachs
- Goldman reiterates $34 target on Kiniksa after 'impressive' data
- 09/29/20 Berenberg
- Roche initiated with a Hold at Berenberg
- 10/20/20 H.C. Wainwright
- Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
- 04/22/20 Cantor Fitzgerald
- Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
- 04/21/20 H.C. Wainwright
- Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
- 01/10/20 Stifel
- Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
- 10/13/20 Roth Capital
- Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
- 08/17/20 H.C. Wainwright
- Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
- 08/05/20
- Fly Intel: Top five analyst initiations
- 08/05/20 Roth Capital
- Inventiva initiated with a Buy at Roth Capital
- 10/07/20 Baird
- iTeos Therapeutics initiated with an Outperform at Baird
- 09/18/20 Piper Sandler
- Piper Sandler lays out next potential takeover targets in oncology
- 09/01/20 Piper Sandler
- iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
- 08/18/20 SVB Leerink
- SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
- 05/22/20 Brookline
- Caladrius initiated with a Buy at Brookline
- 05/18/20 Dawson James
- Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals - 10/01/20 B. Riley Securities
- Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
- 06/01/20 H.C. Wainwright
- Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
- 03/18/20 Roth Capital
- Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
- 02/12/20 Roth Capital
- Streamlining makes Allena URIROX-2 path clear, says Roth Capital
- 09/09/20 Roth Capital
- Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
- 06/23/20 Roth Capital
- Seelos Therapeutics price target raised to $12 from $8 Roth Capital
- 11/18/19 H.C. Wainwright
- Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
SMMNY Siemens Healthineers - 11/10/20 Credit Suisse
- Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
- 10/28/20 Barrington
- Varian Medical downgraded to Underperform from Outperform at Barrington
- 10/26/20 RBC Capital
- Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
- 10/06/20 Deutsche Bank
- Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals - 11/04/20 JMP Securities
- Concert Pharmaceuticals resumed with an Outperform at JMP Securities
- 03/30/20
- Fly Intel: Top five analyst initiations
- 03/30/20 Jefferies
- Concert Pharmaceuticals initiated with a Buy at Jefferies
- 02/27/20 Stifel
- Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
- 10/29/20
- Syneos Health raises FY20 adjusted EPS view to $3.33-$3.46 from $3.16-$3.38
- 10/29/20
- Syneos Health reports Q3 adjusted EPS $1.04, consensus 91c
- 08/06/20
- Syneos Health sees FY20 adjusted EPS $3.16-$3.38, consensus $2.98
- 08/06/20
- Syneos Health reports Q2 adjusted EPS 58c, consensus 48c
- 10/27/20
- Oncolytics announces new GI cancer study using
- 10/15/20
- Roche confirms outlook for 2020 based on assessment of COVID-19
- 10/15/20
- Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year
- 09/11/20
- Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS
- 11/09/20
- RadNet reports Q3 adjusted EPS 15c, consensus (8c)
- 10/20/20
- RadNet executes partnership agreement with Adventist Health
- 08/10/20
- RadNet reports Q2 adjusted EPS (16c), consensus (44c)
- 11/04/20
- Prothena reports Q3 EPS (77c), consensus (65c)
- 08/06/20
- Prothena reports Q2 EPS (66c), consensus (61c)
OPNT Opiant Pharmaceuticals - 11/12/20
- Opiant Pharmaceuticals reports Q3 EPS 15c, consensus (21c)
- 08/06/20
- Opiant Pharmaceuticals reports Q2 EPS (45c), consensus (24c)
- 10/29/20
- Moderna reports Q3 EPS (59c), consensus (43c)
- 10/28/20
- Notable companies reporting before tomorrow's open
- 08/05/20
- Moderna reports Q2 EPS (31c), consensus (35c)
- 10/29/20
- Magellan Health backs 2020 adjusted EPS view 63c-$1.10, consensus 91c
- 10/29/20
- Magellan Health reports Q3 EPS 8c, consensus (10c)
- 07/29/20
- Magellan Health sees FY20 adjusted EPS 63c-$1.10, consensus $2.88
- 07/29/20
- Magellan Health reports Q2 adjusted EPS 84c, consensus 82c
- 11/12/20
- iTeos Therapeutics reports Q3 EPS (48c), consensus (36c)
- 09/01/20
- iTeos Therapeutics reports Q2 EPS ($29.49) vs. ($36.49) a year ago
- 11/12/20
- InMode reports Q3 non-GAAP EPS 63c, consensus 48c
- 10/13/20
- InMode sees FY20 revenue $192M-$195M, consensus $159.91M
- 10/13/20
- InMode sees Q3 non-GAAP EPS 60c-62c, consensus 31c
- 08/05/20
- InMode sees FY20 revenue $156M-$160M, consensus $143.04M
- 11/06/20
- ImmunoGen still sees 2020 revenue $60M-$65M, consensus $66.96M
- 11/06/20
- ImmunoGen reports Q3 EPS (13c), consensus (18c)
- 07/31/20
- ImmunoGen backs 2020 revenue view $60M-$65M, consensus $63.12M
- 07/31/20
- ImmunoGen reports Q2 EPS (14c), consensus (17c)
- 11/05/20
- FibroGen reports Q3 EPS 35c, consensus (80c)
- 08/06/20
- FibroGen sees ending year with $720M-$730M in cash, cash equivalents
- 08/06/20
- FibroGen reports Q2 EPS (95c), consensus (64c)
- 08/10/20
- Esperion sees further cash to be provided from U.S. product sales
- 08/10/20
- Esperion reports Q2 EPS $4.32, consensus $1.71
- 10/29/20
- Charles River sees low-to mid-single-digit percentage growth in Q4 non-GAAP EPS
- 10/29/20
- Charles River raises FY20 EPS view to $7.75-$7.85 from $7.05-$7.35
- 10/29/20
- Charles River reports Q3 EPS $2.33, consensus $1.80
- 08/05/20
- Charles River raises FY20 adj. EPS view to $7.05-$7.35 from $6.75-$7.10
CNCE Concert Pharmaceuticals - 11/05/20
- Concert Pharmaceuticals reports Q3 EPS (60c), consensus (75c)
- 08/06/20
- Concert Pharmaceuticals reports Q2 EPS (41c), consensus (69c)
- 11/05/20
- Caladrius reports Q3 EPS (29c), consensus (29c)
- 08/13/20
- Caladrius reports Q2 EPS (50c), consensus (39c)
- 11/09/20
- Cara Therapeutics reports Q3 EPS (35c), consensus (60c)
- 08/10/20
- Cara Therapeutics reports Q2 EPS (54c), consensus (67c)
- 10/29/20
- AxoGen reports Q3 EPS 4c, consensus (14c)
- 08/05/20
- AxoGen reports Q2 EPS (20c), consensus (38c)
- 07/01/20
- AxoGen sees Q3, Q4 revenue below prior-year levels
- 07/01/20
- AxoGen sees Q2 revenue at least $21M, cosensus $11.67M
ALNA Allena Pharmaceuticals - 11/09/20
- Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c)
- 08/05/20
- Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c)
|
Conference/Events
|
6th Annual Israel Virtual… 6th Annual Israel Virtual Conference will be held on November 12. Webcast Link ShowHide Related Items >><< - 08/06/20
- Zedge promotes Jonathan Reich to CEO, Yi Tsai to CFO
- 07/28/20
- 9 Meters Biopharma issued larazotide-related patent from USPTO
- 07/21/20
- 9 Meters Biopharma doses first patients in Phase 1b/2a clinical trial in SBS
- 06/29/20
- 9 Meters Biopharma amends definition of primary endpoint for larazotide trial
- 06/24/20
- 9 Meters initiates Phase 1b/2a clinical trial in short bowel syndrome
- 11/09/20
- Entera Bio sees cash sufficient into 2Q21
- 11/09/20
- Entera Bio completes enrollment in Phase 2 trial of Eb613
- 08/20/20
- Entera Bio's EB613 shows significant impact in Phase 2 osteoporosis trial
- 08/10/20
- Entera Bio appoints Roger Garceau as interim CEO
- 11/11/20
- Brainsway announces publication of OCD data for Deep TMS system
- 08/24/20
- Brainsway receives 510(k) clearance from FDA for Deep TMS system
- 07/21/20
- University TMS offers Brainsway's Deep TMS therapy
ALNA Allena Pharmaceuticals - 11/09/20
- Allena Pharmaceuticals CFO Edward Wholihan to step down
- 11/09/20
- Allena expects cash, cash equivalents to fund requirement into 4Q21
- 10/05/20
- Allena Pharmaceuticals appoints Ann Miller to board of directors
- 09/30/20
- Allena enters $25M convertible debt financing, extends cash runway into 4Q21
- 03/24/20 Raymond James
- Brainsway price target lowered to $9 from $13 at Raymond James
- 03/24/20 Cantor Fitzgerald
- Brainsway price target lowered to $13 from $17 at Cantor Fitzgerald
- 10/30/20
- Fly Intel: Top five analyst initiations
- 10/30/20 Maxim
- 9 Meters Biopharma initiated with a Buy at Maxim
- 09/23/20 William Blair
- 9 Meters Biopharma initiated with an Outperform at William Blair
- 08/17/20 Brookline
- 9 Meters Biopharma initiated with a Buy at Brookline
ALNA Allena Pharmaceuticals - 10/01/20 B. Riley Securities
- Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
- 06/01/20 H.C. Wainwright
- Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
- 03/18/20 Roth Capital
- Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
- 02/12/20 Roth Capital
- Streamlining makes Allena URIROX-2 path clear, says Roth Capital
- 08/12/20
- Brainsway reports Q2 EPS (3c), two est. (13c)
- 06/24/20
- Brainsway sees Q2 revenue $4.6M-$4.9M, consensus $4.3M
- 06/24/20
- Brainsway reports Q1 EPS (15c), consensus (15c)
ALNA Allena Pharmaceuticals - 11/09/20
- Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c)
- 08/05/20
- Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c)
- 05/13/20
- Allena Pharmaceuticals reports Q1 EPS (31c), consensus (45c)
- 07/22/20
- Fly Intel: After-Hours Movers
|